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ABSTRACT
T Regulatory cells (Treg) play an important role in the induction and maintenance of
immunological tolerance to self and alloantigens. Recent findings in experimental
transplant models have demonstrated that Treg can control acute and delayed allograft
rejection. Preclinical attempts to use Treg as a cellular therapy have been successfully
undertaken demonstrating the safety and feasibility of such treatment, suggesting that they
have therapeutic potential.
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umor formation presents major challenges. Immunosup-
ressive drugs are clearly very efficient at preventing acute
ejection. However, current immunosuppressive therapies
re much less effective at allowing the immune system to
ontinue to respond to antigens other than donor alloanti-
ens after transplantation, as they affect the function of all
esponding T cells irrespective of their antigen specificity.
CD25CD4FOXP3 regulatory T cells are one of the key
populations responsible for controlling immune responses to
alloantigens and preventing rejection in vivo. Thymus derived
or naturally occurring, CD25CD4FOXP3 regulatory T
ells are generated as a distinct population during T cell
evelopment in the thymus.1–4 Importantly for transplanta-
tion, CD25CD4FOXP3 regulatory T cells that are phe-
notypically and functionally similar to the thymus derived
population can also be generated or induced after alloantigen
exposure both in vivo5–10 and ex vivo (for example 11–14). We
have shown, firstly, that regulatory T cells responsive to
alloantigen can arise by both expansion of thymus derived or
naturally occurring regulatory T cells and conversion following
exposure to alloantigen, and secondly, that T cells in the
periphery that are uncommitted to any lineage can be induced
to acquire regulatory function, emphasizing the plasticity of
T cell differentiation following activation.15 In each of these
populations of regulatory T cells, sustained expression of
FOXP3 is essential for maintaining the transcriptional pro-
gramme established during their commitment to become a
regulatory T cell.16
In a transplant recipient, donor alloantigen–reactive reg-
ulatory T cells may develop and their activity be sustained in
a number of different ways. Although alloantigen pretreat-
ment can induce and/or expand alloantigen reactive regu-
latory T cells, as discussed above,5,8 arguably a more
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Open access under CC BY license.mportant source of antigen is the graft itself, as the
mmune system of a transplant recipient is constantly exposed
o donor alloantigens while the graft continues to function. In
mouse model, we demonstrated that the presence of the
llograft as the source of donor alloantigen was essential for
aintaining the unresponsive state.17 This source of antigen is
nique to transplantation and may be important in enabling
OXP3 expression to be stabilized and sustained and/or for
egulatory T cells populations to be renewed in vivo through-
ut the posttransplant course,18 thereby allowing rejection to
e controlled.
Alloantigen induced regulatory T cells can prevent acute,
s well as delayed or chronic graft rejection. In mouse
odels, our own laboratory has demonstrated that regula-
ory T cells induced in response to alloantigen in vivo can
revent the rejection of heart allografts in naïve mice with
n intact immune repertoire,5,19 as well as of heart, skin,
nd islet allografts in more subtle adoptive transfer models
sing immunodificient hosts that enable the mechanisms of
uppression to be investigated.6,8,13 Moreover, these same
opulations of alloantigen reactive regulatory T cells can
revent the development of transplant arteriosclerosis in
ouse and humanized mouse models,20–23 a feature of
allograft rejection that is especially hard to control by
experimental tolerance induction strategies24 and immuno-
suppressive drug therapy.
The specificity of alloantigen reactive regulatory T cells
generated following antigen exposure has been investigated
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2136 WOODin a number of different experimental systems. Our own
data suggest that in vivo, in mice with long-term surviving
allografts, regulatory T cells respond to alloantigen pre-
dominantly via the indirect pathway of allorecognition.6
Understanding where regulatory T cells function to con-
trol rejection at different stages of the immune response
after transplantation is critically important, not least for
defining assays that can be used to assess whether regula-
tory T cells are contributing to graft survival in clinical
transplantation. In experimental models, the draining lym-
phoid tissue has been shown to be the primary, initial site of
interaction between regulatory T cells and naïve T
cells.25–28 Later on, regulation also manifests itself within
the allograft.25,28 Indeed, there are sufficient regulatory T
ells present at some graft sites to enable them to control
ejection when the graft is transferred to a fresh recipient.25
In clinical transplantation, evidence has been obtained that
T cells with the phenotypic characteristics of regulatory
cells are detectable in both the peripheral blood29,30 and
within the graft.31,32
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